Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
CD47-remmer Hu5F9-G4 plus rituximab bij non-hodgkinlymfoom
jan 2019 | Lymfoom